سعر اوليوميانت 4مجم 28 اقراص 2026

Olumiant (baricitinib) 4 mg film-coated tablets, pack of 28, by Eli Lilly; an oral Janus kinase (JAK1/JAK2) inhibitor.

• Moderately to severely active rheumatoid arthritis in adults with inadequate response to one or more TNF blockersPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMOPopulation: Hospitalized adultsDailyMed (U.S. National Library of Medicine)
• Severe alopecia areataPopulation: Adults and pediatric patients 12 years and olderDailyMed (U.S. National Library of Medicine)

• None (US label).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased risk of serious bacterial, fungal, viral and opportunistic infections including tuberculosis; do not give to patients with active TB; test for latent TB before and during therapy (except for COVID-19).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: higher all-cause mortality, malignancy (lymphoma, lung cancer), major adverse cardiovascular events and thrombosis (pulmonary embolism, venous and arterial thrombosis) observed with another JAK inhibitor versus TNF blockers in rheumatoid arthritis; malignancies and thrombosis have occurred with baricitinib.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong OAT3 inhibitors (e.g. probenecid)Baricitinib exposure increases; reduce the baricitinib dose by half.DailyMed (U.S. National Library of Medicine)
• Other JAK inhibitors, biologic DMARDs, potent immunosuppressants (azathioprine, cyclosporine)Combination not studied / not recommended.DailyMed (U.S. National Library of Medicine)

• Based on animal reproduction studies baricitinib may cause fetal harm; human data are insufficient to inform drug-associated risk; consider risks and benefits of chronic use during pregnancy. A pregnancy exposure registry exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No human milk data; baricitinib is present in rat milk. Advise not to breastfeed during treatment and for 4 days after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Baricitinib: Janus kinase (JAK) inhibitor (JAK1/JAK2) that modulates cytokine and growth-factor signalling involved in inflammation and immune function (US label class statement).